NCT06430931

Brief Summary

This prospective study aims to assess the efficacy of the OviTex 1S permanent mesh in pelvic floor surgery in comparison with the current standard polypropylene mesh.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
184

participants targeted

Target at P75+ for not_applicable

Timeline
14mo left

Started Dec 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Dec 2023Jul 2027

Study Start

First participant enrolled

December 6, 2023

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 2, 2024

Completed
26 days until next milestone

First Posted

Study publicly available on registry

May 28, 2024

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

January 2, 2026

Status Verified

December 1, 2025

Enrollment Period

3.6 years

First QC Date

May 2, 2024

Last Update Submit

December 31, 2025

Conditions

Keywords

ProlapseAbdominal prolapse SurgeryBiological meshOviTexVMRsacrocolporectopexy

Outcome Measures

Primary Outcomes (3)

  • Main study parameter/endpoint phase II: rate of complications

    Post-operative complications. The Clavien Dindo Classification is used to rank the severity of a surgical complication

    90days postoperative

  • Main study parameter/endpoint phase ll: number of participants with post-operative morbidity

    Post-operative morbidity measured by reoperations, reinterventions, readmissions,

    90days postoperative

  • Main study parameter/endpoint phase Ill: Pelvic Floor Distress lnventory-20 score (PFDl-20)

    Constipation, incontinence and urogenital functioning (questionnaire, validated scoring system: Pelvic Floor Distress lnventory-20 (PFDl-20). The Pelvic Floor Distress Inventory-20 (PFDI-20) is a questionnaire used to assess the presence and severity of symptoms related to pelvic floor disorders. The PFDI-20 consists of 20 questions divided into three subscales: the Pelvic Organ Prolapse Distress Inventory (POPDI), the Colorectal-Anal Distress Inventory (CRADI), and the Urinary Distress Inventory (UDI). Scale Details: Minimum Score: 0 Maximum Score: 300 Interpretation: Higher scores indicate a worse outcome, reflecting greater distress or more severe symptoms.

    24 months postoperative

Secondary Outcomes (13)

  • Constipation

    24 months postoperative

  • Incontinence

    24 months postoperative

  • Quality of life (Qol) pre- and postoperatively by the Patient Global Impression of Improvement (PGl-I).

    24 months postoperative

  • Quality of life (Qol) pre- and postoperatively by the Patient Global Impression of Severity (PGl-S).

    24 months postoperative

  • Quality of life (Qol) pre- and postoperatively by the European Quality of Life Five Dimension (EQ-5D).

    24 months postoperative

  • +8 more secondary outcomes

Study Arms (2)

Polypropylene mesh

ACTIVE COMPARATOR

Polypropylene mesh (Prolene, PMN3, Ethicon Inc Johnson \& Johnson, Amersfoort, The Netherlands; weight 78 g/m2)

Procedure: Minimal invasive abdominal prolapse surgery using Polypropylene mesh

OviTex 1S permanent mesh

EXPERIMENTAL

OviTex Reinforced BioScaffold, Permanent Polymer composed of ovine (sheep) forestomach extracellular matrix (ECM) and polypropylene.

Procedure: Minimal invasive abdominal prolapse surgery using OviTex 1S permanent mesh

Interventions

All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).

Also known as: Ventral mesh rectopexy, Sacrocolporectopexy
Polypropylene mesh

All procedures will be performed with robotic assistance of the da Vinci Si-HD (intuitive Surgical, Inc, Sunnyvale, CA).

Also known as: Ventral mesh rectopexy, Sacrocolporectopexy
OviTex 1S permanent mesh

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Indication for VMR or SCR set by the treating surgeon/gynecologist in accordance to the current guidelines on rectal and pelvic prolapse;
  • Counselled for therapeutic options and given informed consent for VMR or SCR;
  • Counselled for different types of mesh (OviTex or Prolene) and randomisation;
  • Written informed consent for randomisation, OviTex implant or Prolene;
  • Written informed consent for observational data collection.

You may not qualify if:

  • Mentally incompetent patients (unable to fulfil questionnaires).
  • Allergy to ovine rumen.
  • A medical history of pelvic radiation therapy.
  • Scheduled for a redo-rectopexy.
  • A medical history of previously implanted pelvic floor meshes or native tissue.
  • Language barrier

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Meander Medisch Centrum

Amersfoort, Utrecht, 3813TZ, Netherlands

RECRUITING

MeSH Terms

Conditions

ProlapseRectal ProlapseRectoceleUterine ProlapseCystoceleHernia

Condition Hierarchy (Ancestors)

Pathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsRectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesPelvic Organ ProlapseUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital Diseases

Study Officials

  • Esther Consten, Prof.dr

    Meander Medisch Centrum

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Marije Boom, drs.

CONTACT

Esther Consten, Prof.dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Multi-centre prospective non-inferior patient-preference study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Professor

Study Record Dates

First Submitted

May 2, 2024

First Posted

May 28, 2024

Study Start

December 6, 2023

Primary Completion (Estimated)

July 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

January 2, 2026

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

De-identified individual participant data will be shared upon reasonable request after publication of the primary study results. Data will be available for academic research purposes, subject to approval of a research proposal and a data sharing agreement. Requests should be addressed to the principal investigator.

Shared Documents
STUDY PROTOCOL
Time Frame
After publication of the primary study results.

Locations